Eli Lilly Announces FDA Breakthrough Therapy Designation For Olomorasib Monotherapy In Previously Treated KRAS G12C-Mutant Advanced Pancreatic Cancer, Second Such Designation For Drug

Benzinga Newsdesk www.benzinga.com Positive 89.5%

Neg 0% Neu 0% Pos 89.5%

Comments

No comments yet. Be the first!